Physician profile
Miri Sinclair
NPI 1780671636
$3,983.60
in general payments reported to CMS, 2019-2025
31 companies · $606 in 2025
The $606 reported for 2025 was more than what 77% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,022 · 2022: $360 · 2023: $792 · 2024: $1,204 · 2025: $606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,374 · Education: $228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,373.73 |
| Education | $228.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $818.76 | 2023-2025 | Rybrevant, Erleada, Tecvayli |
| Astrazeneca Pharmaceuticals Lp | $381.49 | 2021-2025 | Enhertu, Tagrisso |
| Daiichi Sankyo INC. | $261.38 | 2021-2025 | Enhertu, Vanflyta, Datroway |
| Glaxosmithkline, LLC. | $260.29 | 2021-2023 | Jemperli, Zejula |
| E.R. Squibb & Sons, L.L.C. | $231.90 | 2022-2024 | Opdivo |
| Novartis Pharmaceuticals Corporation | $195.95 | 2021-2024 | |
| Incyte Corporation | $166.87 | 2021-2023 | Pemazyre, Monjuvi |
| Eisai INC. | $160.87 | 2021-2024 | |
| Genentech USA, INC. | $153.25 | 2021 | |
| Paratek Pharmaceuticals, INC. | $144.26 | 2024 | Nuzyra |
| Lilly USA, LLC | $130.17 | 2024 | Jaypirca |
| Celgene Corporation | $126.83 | 2022-2024 | Reblozyl, Pomalyst |
| Emd Serono, INC. | $125.00 | 2023 | Bavencio |
| Kyowa Kirin, INC. | $120.96 | 2021 | |
| Pharmacosmos Therapeutics INC. | $117.06 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $75.39 | 2023-2024 | |
| Amgen INC. | $73.99 | 2021 | |
| Puma Biotechnology, INC. | $68.60 | 2023 | |
| Astellas Pharma US INC | $58.54 | 2023-2024 | Cresemba, Padcev |
| Gilead Sciences, INC. | $53.24 | 2022-2023 | |
| Sun Pharmaceutical Industries INC. | $34.49 | 2024 | |
| Immunogen, INC. | $28.89 | 2023 | Elahere |
| Sanofi-Aventis U.S. LLC | $25.14 | 2024 | |
| Sobi, INC | $25.08 | 2024 | |
| Stemline Therapeutics INC. | $24.80 | 2024 | Orserdu |
| Merck Sharp & Dohme LLC | $24.10 | 2023 | |
| Abbvie INC. | $22.98 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $20.81 | 2024 | Tazverik |
| Adc Therapeutics America, INC. | $20.61 | 2024 | |
| Beone Medicines USA, INC. | $17.16 | 2025 | Tevimbra |
| Seagen INC. | $14.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miri Sinclair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.